- Home
- SOS vs CELU Comparison
SOS vs CELU Comparison
Compare SOS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOS | CELU |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 17.3M |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SOS | CELU |
|---|---|---|
| Price | $0.98 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 60.6K | 40.6K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,550,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.75 | $0.56 |
| 52 Week High | $2.48 | $4.01 |
Technical Indicators
Market Signals| Indicator | SOS | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 57.18 |
| Support Level | $0.93 | $0.69 |
| Resistance Level | $1.12 | $0.83 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 70.21 | 57.19 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.